Silo Pharma, Inc. — Director's Dealing 2023

May 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2023-05-17

Reporting Person: Weisblum Eric (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-17	Common Stock	P	2500	$2.060	Acquired	157224	Direct
2023-05-18	Common Stock	P	500	$2.107	Acquired	157724	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.000 to $2.0899. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at $2.104 and $2.109. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.